Insilico Medicine's chief scientific officer (CSO) and Head of R&D
Dr. Feng Ren received his Ph.D. degree in chemistry from Harvard University in 2007. He then spent 11 years in the discovery and development of small molecule innovative drugs at GlaxoSmithKline (GSK), where he served as the principal scientist, program leader, director and head of chemistry of Neurodegeneration DPU, a global drug R&D unit in neurosciences in GSK.
In his career Dr. Ren successfully developed multiple preclinical candidate compounds/clinical phase I compounds for the treatment of non-small cell lung cancer, multiple sclerosis, psoriasis, inflammatory bowel disease, Parkinson's disease, and neuropathic pain.
In 2021, Dr. Ren joined Insilico Medicine as CSO, responsible for internal pipelines and external collaborations in drug discovery and development.
Visit website: https://insilico.com/team#ren-feng
See also: Insilico Medicine - Biotechnology company that uses artificial intelligence to develop new drugs and for aging research
Ren Feng News
Insilico Medicine series D funding to grow its pipeline and create an AI-driven robotic drug discovery laboratory
Longevity Technology - 06-Jun-2022
Big data combined with laboratory automation - the pace of drug discovery is about to take off!Read more...